Article

Ellipta Shows Superior Rates of Correct Patient Use Compared with Device Combos

Author(s):

A new study has found that patients with chronic obstructive pulmonary disease (COPD) better manage proper inhaler use with 1 branded single-use device than others.

A new study has found that patients with chronic obstructive pulmonary disease (COPD) better manage proper inhaler use with 1 branded single-use device than others.

Triple-therapy single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Ellipta) showed superior rates of correct patient use and reduced health care provider instruction in a multicenter, single-visit, randomized, open-label, crossover study that compared the GlaxoSmithKline (GSK)-manufactured device to 3 of its market competitors.

The study, funded by GSK, was presented at the 2018 American Thoracic Society (ATS) International Conference in San Diego, CA. The compared therapies included fluticasone/salmeterol (Diskus), tiotropium (HandiHaler), and budersonide/formoterol (Turbuhaler).

Click to continue reading on MD Magazine.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Doctor diagnosing patient’s health on asthma, lung disease, COVID-19 or bone cancer illness with radiological chest x-ray film for medical healthcare hospital service - Image credit: Chinnapong | stock.adobe.com
Adult and child hands holding lung, world tuberculosis tb day, world no tobacco day, lung cancer, long covid, COPD, eco air pollution, organ donation concept - Image credit: SewcreamStudio | stock.adobe.com
Asthma COPD Breath Nebulizer And Mask Given By Doctor Or Nurse - Image credit: Angelov | stock.adobe.com